IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Ranbaxy Buys 13 Drugs from BMS

7:04 AM MDT | August 6, 2007 | Chemical Week Editorial Staff

Ranbaxy Laboratories Inc. (RLI; Princeton, NJ), a wholly owned subsidiary of Ranbaxy Laboratories (Gurgaon, India), says it has acquired the U.S. rights to 13 dermatology products from Bristol-Myers Squibb (BMS). The U.S. dermatology market is valued at about $10 billion/year. The acquired brands have been in the market for more than a decade. They will be sold in the U.S. market under the RLI label. The deal “enables Ranbaxy to establish an immediate presence in the high-value segments of dermatitis, psoriasis, antifungals, and scabies, in addition to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa